JPMorgan initiates Kura Oncology stock with overweight rating
Covered in this story
What has happened since
- Kura Oncology Inc is up 0.2% since this was published, 6 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
JPMorgan’s $30 target on $KURA is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
JPMorgan’s track record →Analyst targets on Kura Oncology Inc
- UBS: $10.7 → $15 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $KURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Kura Oncology Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.